Background and purpose: This study analyzed 1-

3- and 5-year observed overall survival (OS) from a hospital-based cancer registry database

providing real world evidence of long-term survival among Chinese surgical lung cancer patients. Methods: A total of 7 753 lung cancer patients who underwent surgery in Fudan University Shanghai Cancer Center (FUSCC) from Jan. 1

2008 to Dec. 31

2017 were included in this analysis. Medical record review

telephone visits and death registry data linkage were carried out for collecting endpoint data. The last follow-up date was Nov. 30

2019. Kaplan-Meier method was used to evaluate the 1-

3- and 5-year OS rates

and results were described according to age group

smoking status

diagnosis time

tumor stage by gender. Results: The 5-year OS rate was 69.0% in male lung cancer patients who underwent surgery with a median follow-up time of 49.7 months and 82.9% in female patients with a median follow-up time of 43.0 months

which was significantly better for female patients. The 5-year OS rates were 100.0%

86.0%

74.6%

66.9%

55.2%

42.5% and 41.8% in male patients and 100.0%

93.7%

78.5%

78.2%

62.9%

49.3% and 33.0% in female patients with stage 0

ⅠA

ⅠB

ⅡA

ⅡB

ⅢA and ⅢB lung cancer

respectively. Female patients in stage ⅠA

ⅠB and ⅢA groups had better OS than male patients. Conclusion: This study is the 5-year long-term survival result report of the largest single-center lung cancer patients in China. The survival of lung cancer patients after standardized treatment is significantly improved. The survival of female lung cancer patients after surgery is better than that of male lung cancer patients. Tumor stage is an important factor affecting the survival of patients with lung cancer

and early diagnosis and treatment should be strengthened to further improve the survival of patients.